Surgery and Thrombolysis for Ischemia of the Lower Extremity trial halted after interim analysis of first 300 patients shows advantage for surgery over thrombolytic therapy for treatment of peripheral arterial occlusion (PAO). According to Genentech, the thrombolytic arm (using either Genentech's Activase or Abbott's Abbokinase) was hampered by a "mechanical difficulty" in "placing the catheter delivering the drug into the clot." Genentech said it will continue to study Activase for PAO subpopulations. The company plans to begin trials in patients at high risk of amputation and in acute PAO patients during the current quarter.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth